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ABSTRACT
Objective Assess the effects of belimumab treatment
plus standard systemic lupus erythematosus (SLE) therapy
on health-related quality of life (HRQOL) in patients with
active, autoantibody-positive SLE.
Methods Patients received standard therapy plus
placebo or belimumab 1 or 10 mg/kg in two multicentre,
randomised controlled trials of 52 (BLISS-52; N=865)
and 76 (BLISS-76; N=819) weeks’ duration. Responders
were evaluated by SLE Responder Index at week 52.
Patient-reported outcome assessments included SF-36,
Functional Assessment of Chronic Illness Therapy
(FACIT)-Fatigue, and EQ-5D.
Results Mean SF-36 Physical Component Summary
(PCS) scores at week 24 was a major secondary
endpoint. Baseline SF-36 scores were 1.5 SDs below
age-/sex-matched US norms with similar improvement at
week 24 across treatment groups. Mean changes from
baseline in PCS scores were significantly (p<0.05)
greater with belimumab 1 mg/kg (4.20) and 10 mg/kg
(4.18) versus placebo (2.96) in BLISS-52, week 52. In
BLISS-76, significantly (p<0.05) greater improvements
were seen with belimumab 1 mg/kg in PCS (belimumab
1 mg/kg=4.37, 10 mg/kg=3.41 vs placebo=2.85) and
Mental Component Summary (MCS) scores (belimumab
1 mg/kg=3.14, 10 mg/kg=2.70 vs placebo=1.40) at
week 52, and in MCS score at week 76 (belimumab
1 mg/kg=3.05, 10 mg/kg=2.28 vs placebo=1.36). In
pooled analysis, significantly greater improvements in
PCS, SF-36 vitality domain, and FACIT-Fatigue scores at
week 52 were evident with both belimumab doses.
Conclusions The clinically meaningful improvements in
HRQOL in autoantibody-positive patients with active SLE
treated with belimumab and standard therapy are
consistent with the reductions in disease activity




Systemic lupus erythematosus (SLE) is a chronic
multisystem autoimmune disease that may affect
multiple body organs and systems, and is charac-
terised by relapses and remissions.1 2 Patients with
SLE have an increased risk for mortality compared
with age-matched and sex-matched healthy sub-
jects, as well as for comorbidities resulting from the
disease and its treatment, which adversely affect
health-related quality of life (HRQOL).1 3 The
effects of SLE on HRQOL are comparable with, or
worse than, those of other chronic diseases, such as
AIDS, rheumatoid arthritis, diabetes and congestive
heart failure.2 4–6 Fatigue is a common complaint
of patients with SLE, and is associated with poor
physical and mental functioning.7
B-lymphocyte stimulator (BLyS), an immunomodu-
latory cytokine that promotes B-cell survival and dif-
ferentiation, and immunoglobulin class switching, is
overexpressed in many patients with autoimmune dis-
eases, including SLE.8 9 Significant associations have
been observed between plasma BLyS levels and
markers of SLE disease activity.9 Belimumab is a
human, immunoglobulin-G1λ monoclonal antibody
that inhibits the biologic activity of soluble BLyS.10
In two phase 3, randomised, double-blind, multicen-
tre, placebo-controlled trials (BLISS-52 (N=865;
ClinicalTrials.gov identifier NCT00424476) and
BLISS-76 (N=819; NCT00410384)), belimumab
treatment was efficacious with an acceptable safety
profile in patients with autoantibody-positive
SLE.11 12 This report presents the results of patient-




Details of the trial designs and methods–similar in
both BLISS-52 and BLISS-76–have been described
previously.11 12 The trials were conducted in
accordance with the Declaration of Helsinki. The
protocols were reviewed and approved for all study
sites by a central institutional review board, and all
patients provided written informed consent. In
brief, adult patients with SLE who were autoanti-
body positive (antinuclear antibody titre ≥1 : 80, or
antidouble-stranded DNA antibodies ≥30 IU/ml)
and had active disease (Safety of Estrogens in
Lupus Erythematosus National Assessment-SLE
Disease Activity Index (SELENA-SLEDAI) score
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≥6) at screening were enrolled, having received a stable regimen
of standard SLE therapy for ≥30 days, including prednisone,
and nonsteroidal anti-inflammatory, antimalarial and immuno-
suppressive drugs. Exclusion criteria included severe active SLE
nephritis or severe central nervous system manifestations of
lupus. In addition to standard therapy, patients were randomly
assigned to receive placebo, or belimumab 1 or 10 mg/kg. These
studies were designed to compare belimumab with placebo, as
all patients were receiving active therapy prior to enrolment and
during the trials. Treatments were administered intravenously on
days 0, 14 and 28, and every 28 days thereafter through week
48 in BLISS-52 and week 72 in BLISS-76. The primary efficacy
endpoint was SLE Responder Index (SRI) rate at week 52.13 To
be considered an SRI responder, a patient had to have a
≥4-point reduction in SELENA-SLEDAI score, no new British
Isles Lupus Assessment Group A and <2 new B scores, and ‘no
deterioration’ (eg, <0.3-point increase) in Physician’s Global
Assessment score at week 52 compared with baseline.
A major secondary endpoint was mean change in SF-36v2
Health Survey Physical Component Summary (PCS) scores at
week 24.11 12 Additional prespecified secondary endpoints
included mean changes from baseline in SF-36 PCS, Mental
Component Summary (MCS), and domains, Functional
Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)
V.4, and EQ-5D scores at weeks 12, 24, 52 and 76 (BLISS-76
only). Additional posthoc analyses were performed using data
from these measures.
The SF-36 is a generic, validated questionnaire that assesses
HRQOL during the previous 4 weeks in 8 domains, including
physical functioning, role-physical, bodily pain, general health,
vitality, social functioning, role-emotional and mental
health.14 15 It has been validated and tested in many SLE trials
and across cultures.6 16 17 Raw domain scores are converted to
a 0–100 scale, with higher scores indicating better health. These
scores are Z-transformed and weighted to yield values used to
calculate PCS and MCS scores, which are norm based with a
mean of 50 and SD of 10. Minimum clinically important differ-
ences (MCID) for improvement and deterioration, respectively,
in summary scores are +2.5 and −0.8, and +5.0 and −2.5 for
domain scores.18 SF-36 also includes a transition
question–‘Compared to 1 year ago, how is your general health
today?’–which includes five response categories from ‘much
worse’ to ‘much better’.
Spydergrams present data for each SF-36 domain along indi-
vidual spokes, ranging from 0 (worst health) to 100 (best
health) and have been used to visualise HRQOL changes in
response to treatment in patients with autoimmune diseases;
gridlines represent 10 points, for instance, 2× MCID.19 20
Mean SF-36 domain scores in patients at baseline and week 52
in both BLISS studies were compared with age-matched and sex-
matched healthy US subjects. With the innermost polygon repre-
senting baseline SF-36 domain values for SLE patients in the
BLISS studies, and the outermost polygon representing domain
scores of comparable healthy subjects, mean improvements from
baseline with treatment are illustrated by the intermediate rings.
The FACIT-Fatigue scale is based on a 13-question question-
naire that assesses fatigue during the previous 7 days, scored
from 0 to 52 (worst); MCID is 4.0. The FACIT-Fatigue scale has
been validated in patients with rheumatoid arthritis.18 21 22
The EQ-5D questionnaire provides a profile of five dimen-
sions (ie, mobility, self-care, usual activities, pain/discomfort and
anxiety/depression), with three responses for each: ‘no’, ‘some
or moderate’, and ‘severe’ problems.23 A summary index is cal-
culated by weighting the answers based on health states in a
population sample. In the present study, EQ-5D scores were cal-
culated using US and UK value sets.23 24 The index ranges from
1 (perfect health) to <0, which represents the worst imaginable
state of health. The EQ-5D includes the EuroQoL visual ana-
logue scale (EQ VAS), a vertical 20 cm VAS used to score the
patient’s health perception, with 100 representing the best and
0 the worst health.
The SF-36, FACIT-Fatigue, and EQ-5D were administered at
baseline, and weeks 4, 8, 12, 24 and 52 in both trials, and add-
itionally at weeks 20, 32, 40, 48, 68 and 76 in BLISS-76 and
week 36 in BLISS-52.
Statistical analyses
Primary analyses were evaluated by individual study. Changes
from baseline in SF-36, FACIT-Fatigue, and EQ-5D scores were
analysed using a covariance model, with covariates for baseline
value and the three stratification factors, including baseline
SELENA-SLEDAI score (≤9 vs ≥10), baseline proteinuria level
(<2 g/24 h vs ≥2 g/24 h equivalent), and race (African descent
or indigenous American descent vs other). The trial was also a
covariate for the prespecified pooled analyses. The last observa-
tion was carried forward to account for missing data in SF-36
and FACIT-Fatigue analyses, whereas only observed values were
included in the EQ-5D analysis. Where baseline data are pre-
sented as combined for all treatment groups, significance testing
was based on change from baseline within each treatment
group. Nominal p values are from pairwise comparisons of
active treatments versus placebo, and a value <0.05 was consid-
ered significant. Due to the similar study designs of BLISS-52
and BLISS-76, data from both trials were pooled by treatment
group for analyses in HRQOL measures.11 12
RESULTS
Baseline characteristics
Patient demographics and disease characteristics were well
balanced between treatment groups within each trial at baseline
(table 1).11 12 There were, however, some differences between
the BLISS-52 and BLISS-76 study populations in race, age,
disease duration and activity, and types of background standard
therapies used that can, in part, be attributed to the varied geo-
graphic locations of the studies. Patients in BLISS-76 had a
longer duration of SLE and more damage, as measured by the
Systemic Lupus International Collaborating Clinics Damage
Index, whereas those in BLISS-52 were more serologically
active. The proportions of patients taking prednisone, and mean
prednisone (or equivalent) doses were higher, and immunosup-
pressant use was lower in BLISS-52 than in BLISS-76. Baseline
SF-36 scores in both study populations were lower than those
of an age-matched and sex-matched US population.
Primary efficacy endpoint
As previously reported, SRI rates at week 52 in BLISS-52 were
significantly higher with belimumab 1 mg/kg (51%; p=0.01)
and 10 mg/kg (58%; p<0.001) than with placebo (44%); corre-
sponding rates were 41% (p=0.09) and 43% (p=0.02) vs
33.5% in BLISS-76, and 46% (p=0.006) and 51% (p<0.001)
vs 39% in pooled analysis.11 12
SF-36 outcomes
Baseline PCS scores were lower than MCS scores in both trials:
∼1 (BLISS-52) and 1.5 (BLISS-76) SDs below normative values
of 50 (table 1 and figure 1). Mean PCS scores improved from
baseline to week 24 in all treatment groups, but were not signifi-
cantly different between groups (major secondary endpoint).11 12
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Both PCS and MCS scores improved over time, and were greater
with belimumab than placebo in both trials at week 52 (figure 1).
In BLISS-52, patients in both belimumab treatment groups
reported significantly greater improvements (p<0.05) in PCS
scores versus placebo at week 52 (belimumab 1 mg/kg=4.20 and
belimumab 10 mg/kg=4.18 vs placebo=2.96). In BLISS-76,
improvements in PCS and MCS scores were significantly greater
with belimumab 1 mg/kg versus placebo at week 52 (PCS:
belimumab 1 mg/kg=4.37 vs placebo=2.85 and MCS: belimumab
1 mg/kg=3.14 vs placebo=1.40; both p<0.05), and in MCS
scores at week 76 (belimumab 1 mg/kg=3.05 vs placebo=1.36;
p<0.05), whereas mean changes in PCS and MCS scores with beli-
mumab 10 mg/kg were not significantly different (PCS week
52=3.41, MCS week 52=2.70, and MCS week 76=2.28). Pooled
data showed significantly greater improvements at week 52 in PCS
scores with both belimumab doses versus placebo (p<0.05), and in
MCS scores with 1 mg/kg (p<0.01).
The spydergram in figure 2A illustrates the mean SF-36
domain scores at baseline and week 52 in BLISS-52 patients
compared with age-matched and sex-matched US subjects. The
mean scores of healthy subjects serve as a benchmark compara-
tor, and the large decrements from normative values at baseline
across all domains reveal the broad impact of active SLE in
patients. In BLISS-52, mean changes from baseline at week 52
were significantly higher in the physical functioning, bodily pain
and role-emotional domains with both belimumab doses, in the
social functioning and general health domains with belimumab
1 mg/kg, and in the vitality domain with 10 mg/kg versus
placebo (p<0.05 for all). Reported improvements from baseline
in all eight domains with belimumab 1 and 10 mg/kg exceeded
placebo and were ≥MCID.
In BLISS-76, reported improvements with belimumab
1 mg/kg in the SF-36 role-physical, bodily pain, general health
and vitality domains at week 52 were significantly different
from placebo, and mean changes from baseline in all eight
domains were ≥MCID. Patients receiving belimumab 10 mg/kg
did not report statistically significant improvements, although all
except the role-emotional domain score were clinically meaning-
ful (≥MCID) (figure 2B). The impact of SLE on HRQOL was
more evident in BLISS-76 than in BLISS-52, reflecting increased
disease duration and more severe disease activity, as indicated by
lower baseline SF-36 domain scores.
In the pooled phase 3 studies, mean changes from baseline at
week 52 were significantly higher in the physical functioning,
bodily pain, general health and vitality domains with both
belimumab doses, and in the social functioning and role-
emotional domains with belimumab 1 mg/kg versus placebo
(p<0.05 for all). In all eight domains, reported improvements
from baseline with belimumab 1 and 10 mg/kg were ≥MCID,
and all except the role-physical domain for belimumab 10 mg/kg
exceeded improvements with placebo treatment (figure 2C).
In BLISS 52, responses to the SF-36 transition question at
week 52 indicated that patients receiving belimumab versus
placebo reported their health as being ‘better’ or ‘much better’
than 1 year prior (64.2% and 64.5% with 1 and 10 mg/kg,
respectively, vs 52.6% with placebo; p<0.01). In BLISS-76, dif-
ferences were not statistically significant (although numerically
greater) in the belimumab groups at weeks 52 (47.2% and
45.2% with 1 and 10 mg/kg, respectively, vs 41.5% with
placebo) and 76 (41.7% and 41.4% vs 38.2%). In pooled ana-
lysis, 56% (p=0.003) and 55% (p=0.007) of patients receiving
belimumab 1 and 10 mg/kg, respectively, reported that their
health was ‘better’ or ‘much better’ versus 47% receiving
placebo.
FACIT-Fatigue outcomes
Although FACIT-Fatigue scores were not significantly different
across treatment groups at the week-24 prespecified secondary
endpoint, scores from baseline to week 52 improved signifi-
cantly (p<0.05) with belimumab 1 and 10 mg/kg vs placebo in
BLISS-52, and with 1 mg/kg at weeks 52 and 76 secondary end-
points in BLISS-76 (figure 3A,B). While differences observed
between belimumab 10 mg/kg and placebo were not statistically
Table 1 Baseline demographics and patient characteristics
BLISS-52 (N=865) BLISS-76 (N=819)
Region/country, %
US/Canada – 53.2
Western Europe/Israel – 24.7
Americas excluding US/Canada 49.5 10.7
Asia–Pacific 39.2 –
Eastern Europe 11.3 11.4










Mean SLE duration±SD, years 5.3±5.3 7.5±7.1
Mean SELENA-SLEDAI±SD 9.8±3.8 9.7±3.8
BILAG 1 A or 2 B, % 58.3 63.5
BILAG 1 A, % 19.0 12.1
Mean SLICC damage index score 0.57 1.00
ANA ≥1 : 80, % 93.9 92.1
Anti-dsDNA ≥30 IU/ml, % 74.5 64.0
Low C3 (<90 mg/dl), % 49.4 40.4
Low C4 (<16 mg/dl), % 59.3 52.6
Anti-dsDNA and low C3/C4, % 55.5 44.5
Prednisone use, % 96.0 76.1
Mean prednisone±SD, mg/d† 12.7±8.4 8.8±8.2
Dose >7.5 mg/d, % 69.4 45.9
Immunosuppressive use, %‡ 42.2 55.6
Antimalarial use, % 67.2 63.4
HRQOL scores
SF-36 PCS, n 853 813
Mean score±SD 41.5±9.0 36.5±9.7
SF-36 MCS, n 853 813
Mean score±SD 40.7±10.5 41.0±12.0
SF-36 vitality, n 863 816
Mean score±SD 48.9±20.3 37.2±21.8
FACIT-Fatigue, n 842 812
Mean score±SD 33.5±10.2 26.6±12.4
*Alaska native or American Indian from North/South/Central America.
†Prednisone or prednisone equivalent.
‡Includes azathioprine, azathioprine sodium, ciclosporin, cyclophosphamide,
leflunomide, methotrexate, methotrexate sodium, mizoribine, mycophenolate mofetil,
mycophenolate sodium, mycophenolic acid and thalidomide.
ANA, antinuclear antibody; anti-dsDNA, antidouble-stranded DNA; BILAG, British Isles
Lupus Assessment Group; C, complement; FACIT, Functional Assessment of Chronic
Illness Therapy; HRQOL, health-related quality of life; MCS, Mental Component
Summary; PCS, Physical Component Summary; SELENA-SLEDAI, Safety of Estrogens in
Lupus Erythematosus National Assessment−Systemic Lupus Erythematosus (SLE)
Disease Activity Index; SF-36, Short Form-36; SLE, systemic lupus erythematosus;
SLICC, Systemic Lupus International Collaborating Clinics.
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significant in BLISS-76, numerical improvements over placebo
were observed by week 8 and sustained through week 76.
In pooled analysis, FACIT-Fatigue scores were significantly
improved (p<0.05) with both belimumab dosages at week 52
(figure 3C), as well as weeks 8 and 12 (data not shown).
Reported improvements in FACIT-Fatigue were associated
with those in the SF-36 vitality domain, where statistically sig-
nificant improvements (mean change from baseline±SE) with
belimumab versus placebo were reported at weeks 8
(7.58±0.78) and 12 (8.49±0.84) with 10 mg/kg (both p<0.05),
Figure 2 Spydergrams of composited baseline (BL) and week-52 SF-36 domain scores by treatment group versus US age-/gender (A/G)-matched
norms in (A) BLISS-52, (B) BLISS-76, and (C) pooled analysis. Inner polygon (deep purple) represents weighted mean BL SF-36 domain scores across
all three treatment groups; outer polygon (yellow) represents A/G norms as a benchmark comparison; mean changes with placebo, and belimumab
1 and 10 mg/kg shown as intermediate polygons (grey, blue, and light purple, respectively). BP, bodily pain; GH, general health; MH, mental health;
PF, physical functioning; RE, role-emotional; RP, role-physical; SF, social functioning; VT, vitality.
Figure 1 Last observation carried forward analysis of mean changes in (A) SF-36 Physical Component Summary and (B) Mental Component
Summary scores for weeks 24 and 52 in BLISS-52 and pooled phase 3 studies, and weeks 24, 52 and 76 in BLISS-76. *p<0.05; †p<0.01. MCID,
minimum clinically important difference.
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and at week 52 with both 1 mg/kg (9.78±0.80; p<0.001) and
10 mg/kg (9.40±0.87; p<0.01). The coefficient of correlation
between FACIT-Fatigue and the SF-36 vitality domain was
0.6998 at week 52.
EQ-5D
In BLISS-52, mean changes from baseline to week 52 in the
EQ-5D utility index (based on the US or UK value set) and VAS
scores were not significantly different between treatment groups
(table 2; UK data not shown). Significant differences were,
however, seen in the percentages of patients with no problems
for the mobility question with belimumab 1 mg/kg and for the
pain/discomfort question with belimumab 10 mg/kg versus
placebo at week 52. In BLISS-76, the EQ-5D VAS score signifi-
cantly improved with belimumab 1 mg/kg at week 52, without
significant between-treatment differences in the utility index or
component questions. In pooled analysis, the only significant
between-treatment difference at week 52 in EQ-5D measures
was for the pain/discomfort question with belimumab 10 mg/kg
versus placebo.
DISCUSSION
Patients receiving belimumab reported clinically meaningful
improvements in HRQOL and fatigue at week 52 versus
placebo in both individual BLISS studies and by pooled analyses.
The major secondary HRQOL endpoint in each trial of greater
improvement in SF-36 PCS in the belimumab treatment arms at
week 24 was not achieved as the improvements were similar in
all treatment groups. However, at week 52, mean PCS scores
improved significantly with belimumab 1 and 10 mg/kg versus
Figure 3 Last observation carried forward analysis of mean changes from baseline in Functional Assessment of Chronic Illness Therapy-Fatigue
and SF-36 vitality domain scores for (A) BLISS-52 at week 52, (B) BLISS-76 at weeks 52 and 76, and (C) pooled phase 3 data at week 52. Higher
scores indicate less fatigue and increased vitality. *p<0.01; †p<0.05; ‡p<0.001. The p values were obtained from an ANCOVA model for the
comparison between each belimumab treatment group and the placebo group. ANCOVA, analysis of covariance; MCID, minimum clinically important
difference.


























Mean utility (US) change from BL±SE 0.05±0.01 0.04±0.01 0.06±0.01 0.05±0.01 0.06±0.01 0.06±0.01 0.05±0.01 0.05±0.01 0.06±0.01
Mobility† – 8.79* 8.07 – 0.31 −0.33 – 4.79 4.16
Self-care† – 4.54 3.98 – 1.35 3.36 – 3.04 3.70
Usual activities† – 1.30 4.01 – 4.77 −5.31 – 2.92 −0.29
Pain/discomfort† – 0.71 9.30* – 6.39 2.85 – 3.38 6.33*
Anxiety/depression† – 4.47 3.93 – 6.17 -0.82 – 5.28 1.71
Mean EQ-5D VAS score change from
BL±SE
9.92±1.18 9.77±1.13 9.99±1.23 7.93±1.34 12.11±1.27* 8.04±1.48 8.99±0.89 10.88±0.85 9.10±0.95
*p≤0.05. The p values were obtained from an ANCOVA model for the comparison between each belimumab treatment group and the placebo group.
†Observed difference from placebo at week 52, %.
ANCOVA, analysis of covariance; BL, baseline; VAS, visual analogue scale.
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placebo in BLISS-52 and the pooled analysis, and with 1 mg/kg
in BLISS-76. Improvements in PCS scores over 52 weeks were
also observed in the phase 2 belimumab dose-ranging trial.25
Mean MCS score improvements were significantly higher
with belimumab 1 mg/kg versus placebo in BLISS-76 and the
pooled analysis. These improvements in patient outcomes are
consistent with the clinical benefits observed in both BLISS
trials.11 12 26–28 Significantly more patients with persistently
autoantibody-positive SLE who received belimumab plus stand-
ard SLE therapy exhibited reduced disease activity than did
those treated with placebo plus standard therapy. The SRI rates
were significantly higher with belimumab 1 and 10 mg/kg in
BLISS-52, and with 10 mg/kg in BLISS-76, versus placebo and
had a greater magnitude of effect in patients with high disease
or serologic activity.28 Further, in pooled analyses, there were
reductions in severe flares and corticosteroid use, and improve-
ments in biomarkers and a variety of organ systems commonly
affected by SLE.11 12 26 27
In BLISS-76, the 1 mg/kg dose HRQOL effect was sometimes
similar to or greater than the 10 mg/kg dose as the SRI treat-
ment effect between belimumab doses was diminished compared
with BLISS-52. In addition, belimumab was added to standard
therapy, for instance, corticosteroids and immunosuppressives.
Changes in this background ‘active’ therapy were allowed;
adjustments to immunosuppressives were allowed through week
16 and to corticosteroids through week 24, with tapering at the
investigator’s discretion over weeks 44–52. This served to
‘rescue’ patients receiving placebo plus standard therapy, and
thereby diminish the differences in responses between each of
the active and control treatment groups.
Divergence in improvements from baseline in some HRQOL
measures between belimumab and placebo became apparent
only after week 24. Given that changes in background medica-
tions were allowed initially, and restricted beginning at week 16
for immunosuppressive and antimalarial agents, and at week 24
for prednisone doses, this is not unexpected. In combined ana-
lyses, consistent with more increases in prednisone doses in
patients receiving placebo11 12 and with successful tapering to
doses ≤7.5 mg qd in patients treated with belimumab,11 12
patient-reported HRQOL and fatigue also improved. Mean
improvements in FACIT-Fatigue scores, which closely correlated
with SF-36 vitality domain scores, were also in accordance with
PCS scores, reflecting significant improvements (that exceeded
MCID for each patient outcome) versus placebo at week 52
with belimumab 1 and 10 mg/kg in BLISS-52 and the pooled
analysis, and with 1 mg/kg in BLISS-76. Consistent responses in
FACIT-Fatigue scores and the SF-36 vitality domain, which also
asks about ‘pep’ and ‘energy,’ are supported by a high correl-
ation (r=0.73–0.84) between these measures in patients with
rheumatoid arthritis.21 Improvement in fatigue in SLE is import-
ant as it remains among the most frequent complaints (occur-
ring in 81% of patients), and can impact overall HRQOL and
the ability to maintain a full-time job.29 30 In addition, the
EQ-5D health utility measure results supported the belimumab
improvements observed in other patient-reported outcomes per-
formed in the BLISS trials.
One of the limitations of this analysis of patient outcomes in
the BLISS trials was that the individual studies were not powered
to detect significant differences in SF-36, FACIT-Fatigue, and
EQ-5D scores with belimumab treatment plus standard therapy
versus standard therapy alone. Posthoc analysis of pooled data,
therefore, shows a more consistent HRQOL and patient-
outcome benefit in patients treated with belimumab than in the
individual trials, where favourable effects on patient outcomes
did not always reach statistical significance. The wide variety of
standard therapies, progressive restriction on concurrent
immunosuppressive therapy, and variable organ system manifes-
tations may have confounded interpretation of the data. Further
study of patient-outcome measures in future belimumab rando-
mised controlled trials in general SLE and lupus nephritis are
needed to validate the findings reported in the present analysis.
In summary, the improvements in patient-reported outcomes
evident in these phase 3 trials were consistent with other
reported clinical benefits of belimumab treatment, such as
reduction in severe flares and corticosteroid use, in patients with
autoantibody-positive SLE who were also receiving standard
SLE therapy.
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